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Idiopathic retroperitoneal fibrosis (IRPF) is a rare disease
characterized by a retroperitoneal inflammatory proliferative
fibrosing process. Hashimoto’s thyroiditis is the most common
inflammatory condition of the thyroid gland; and is a frequently-
occurring autoimmune disorder manifesting predominantly in
middle-aged women. We report a rare association of IRPF
with Hashimoto's thyroiditis in a 67-year-old man demon-
strating good response to steroid therapy.
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INTRODUCTION
Retroperitoneal fibrosis (RPF) is a rare disease
characterized by development of fibrous tissue in
the retroperitoneum. RPF can be classified into
idiopathic and secondary forms depending on the
knowledge of etiology. Secondary RPF is caused
by infections, medications, surgery and malign-
ancies, however only 30 - 40% of all cases of RPF
are secondary. The etiology of most types of RPF
is still unknown, and therefore they are classified
as idiopathic. Because idiopathic retroperitoneal
fibrosis (IRPF) shows response to immunosup-
pressive therapy and is frequently associated with
other autoimmune diseases, it is thought to be a
type of systemic autoimmune disorder. To our
knowledge, only a few cases of IRPF associated
with autoimmune thyroiditis such as Hashimoto's
thyroiditis have been reported. We report a patient
with Hashimoto's thyroiditis in whom concomitant
RPF was diagnosed.
CASE REPORT
A 67-year-old man was referred for biopsy of a
known retroperitoneal mass in April 2006 after
suddenly developing gross hematuria two months
earlier. The patient was diagnosed with Hashimoto's
thyroiditis at a hospital three years previous on the
basis of profound hypothyroidism, markedly in-
creased levels of autoimmune antibody (thyroglo-
bulin antibody 1,587.2 U/mL, normal values: 0 - 60
U/mL; microsomal antibody > 3,000 U/mL, normal
values: 0 - 60 U/mL), and a diffuse hypoechogenic
ultrasonographic pattern. Upon referral in April of
2006, he had been taking levothyroxine to control
his Hashimoto's. Computed tomography (CT) scan
of the abdomen and pelvis at a previous hospital
revealed a retroperitoneal soft tissue mass ex-
tending from the lower pole of the kidney to the
iliac chains, inducing bilateral ureteral obstruction.
The CT did not demonstrate soft tissue between
the aorta and vertebra or lymphadenopathy, ex-
cluding malignancy. A right percutaneous
nephrostomy was also performed at the previous
hospital in order to decompress hydronephrosis
due to the retroperitoneal mass.
On admission, the patient's blood pressure was
140/100 mmHg and body temperature was 36.5 C. ˚
The lungs were clear to auscultation, heart sounds
were within normal limits, and the abdomen was
soft with no masses or tenderness. There was no
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lower extremity edema observed and the thyroid
gland was not enlarged. Results of the complete
blood count, electrolytes, creatinine, urea nitrogen,
protein, albumin, bilirubin, 2-microglobulin and β
lactate dehydrogenase (LDH) were within normal
ranges. Upon immunological testing, immunoglo-
bulin G, C3 and C4 levels remained within normal
ranges. No cytoplasmic antineutrophil cytoplasmic
antibody or cryoglobulin was detected, and anti-
nuclear antibodies and anti-DNA antibodies were
negative. The patient showed signs of hypo-
thyroidism with an elevated thyroid stimulating
hormone (TSH) (69.56 IU/mL, normal values: 0.4 μ
- 3.1 IU/mL) and reduced free T4 (0.83 μ ng/dL,
normal values: 0.73 - 1.95 ng/dL). Upon autoanti-
body screening, the thyroglobulin (1,368.7 U/mL,
normal values: 0 - 60 U/mL) and microsomal
antibodies were elevated (> 3,000 U/mL, normal
values: 0 - 60 U/mL) despite good medication
compliance. After initiating an increased dose of
levothyroxine (0.2 mg), laparoscopic biopsy of the
retroperitoneal mass was performed.
Microscopically, the mass was ill-defined and
composed predominantly of chronic inflammation
and fibrosis. The inflammatory cells were mainly
lymphocytes and plasma cells with the occasional
formation of lymphoid follicles (Fig. 1). Based on
pathologic diagnosis, the patient was started on
deflazacort 72 mg daily. The patient was dis-
charged after 13 days of hospitalization and con-
tinued to receive steroid therapy at the outpatient
clinic. Normal thyroid function was achieved after
two months of steroid treatment; therefore levo-
thyroxine therapy was withdrawn. Steroids were
tapered to 6 mg after two months, which is the
patient's current dose. The patient experienced no
Fig. 1. (A) Laparoscopic biopsy of the retroperitoneal mass shows retroperitoneal fibrosis (hematoxylin-eosin, × 40). (B)
(hematoxylin-eosin, ×200).
Fig. 2. (A) CT demonstrate marked periaortic soft tissue mass surrounding a calcified infrarenal abdominal aorta
compatible with retroperitoneal fibrosis. (B) Follow-up CT after 9 months steroid treatment demonstrated a marked
reduction in the size of retroperitoneal mass (arrow).
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side effects during steroid treatment. Abdominal
ultrasound demonstrated marked reduction of the
retroperitoneal mass and no sign of hydrone-
phrotic change in either kidney. Moreover, an
abdominal-pelvic CT scan performed nine months
after steroid treatment showed reduced mass
lesion in the retroperitoneal space with resolved
right side hydronephrosis (Fig. 2).
DISCUSSION
Since the first description by Ormond in 1948,
1
idiopathic retroperitoneal fibrosis (IRPF) is known
to be a rare disease entity characterized by a retro-
peritoneal inflammatory proliferative fibrosing
process; which is particularly prominent around
great vessels leading to ureteral obstruction.
2 The
incidence of IRPF is unknown and estimates vary
from 1:200,000 - 1:500,000 per year.
3 Hughes et al.
reported that IRPF is a local immune reaction to
lipid components of the atherosclerotic process in
the abdominal aorta, resulting in a proximal
fibrotic reaction.
4 Conversely, others describe IRPF
in association with various other autoimmune
diseases, including primary sclerosing cholangitis,
autoimmune pancreatitis, and systemic lupus
erythematosus;
5,6 suggesting that the pathogenesis
of IRPF is closely related to an autoimmune
abnormality. Because IRPF and other fibrosclero-
sing disorders almost exclusively have infiltrates
of IgG4-positive plasma cells, a new clinicopa-
thological entity such as IgG4-related sclerosing
disease has been recently advocated.
7 This sug-
gests that IRPF is not a homogenous entity, but
rather a heterogenous one.
Until now, most reports regarding the associa-
tion between chronic thyroiditis and IRPF were
cases of Riedel's thyroiditis. Riedel’s thyroiditis is
a rare disease in which the thyroid gland is
replaced by fibrous tissue; and Hay et al. reported
that IRPF followed Riedel’s thyroiditis in 30% of
cases.
8 However, there have been few reports of
IRPF associated with Hashimoto’s thyroiditis,
which is the most common inflammatory condi-
tion of the thyroid gland. So far, only five cases
associating Hashimoto's thyroiditis with IRPF have
been published in English literature.
9-13 The mean
age of all patients was 60 years, with a range from
38 to 71 years, and the female gender was
predominant. Our patient was a 67-year-old man,
unlike the previous reports. Including the present
patient, three out of five cases showed IRPF prior
to autoimmune thyroiditis, and in one case
autoimmune thyroiditis appeared after retro-
peritoneal fibrosis. In the remaining case the two
diseases occurred simultaneously, suggesting a
need to monitor patients with retroperitoneal
fibrosis for development of autoimmune thyroiditis.
It is difficult to distinguish Riedel's thyroiditis
from the fibrosing variant of Hashimoto's thyro-
iditis. Nearly all patients with Hashimoto's thyro-
iditis have high serum concentrations of auto-
antibodies and profound hypothyroidism.
14
Although Riedel's thyroiditis is known to show
less association with autoantibody, elevated auto-
immune antibody levels could be observed in 67%
of Riedel's thyroiditis.
15 However, most patients
with Riedel's thyroiditis are euthyroid, whereas
few are hypothyroid.
16 Therefore, we think the
present case fits the clinical picture of Hashimoto's
thyroiditis. Histological confirmation would be
necessary for a more accurate diagnosis; but we
could not define a definite goiter or mass, making
aggressive biopsy difficult.
Usual management of the disease consists of
surgical relief of the ureteral obstruction, followed
by corticosteroids for the prevention of recur-
rence.
17,18 Five of the previously-reported cases
used a modest dose (20 - 30 mg) of prednisolone
for treatment, which resulted in optimistic results
in terms of retroperitoneal fibrosis and goiter size.
Moulik et al. made a report on steroid responsive-
ness in a case of Riedel's thyroiditis and IRPF.
19
They used a modest dose of prednisolone (30 mg
daily) and stopped it after 8 - 10 months, ob-
serving a decrease in the patients' thyroglobulin
antibodies and thyroid peroxidase antibodies. In
our case, 72 mg/day of deflazacort was initially
prescribed and the dose was then decreased to 6
mg/day. Unlike previous cases which maintained
75- 150mcg levothyoxine continuously, we stopped
levothyroxine once hypothyroidism was well con-
trolled with deflazacort. We also observed near-
disappearance of the retroperitoneal mass after
steroid treatment. Since the diseases developed
concurrently and both showed a positive response
to steroid therapy, our case may suggest an etio-IRPF Associated with Hashimoto's Thyroiditis
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logic association between the two diseases and
autoimmune pathogenesis of IRPF. Recently, as
mentioned above, Kimisawa et al. proposed the
existence of a new entity, "IgG4-related sclerosing
disease", incorporating sclerosing pancreatitis,
cholangitis, and retroperitoneal fibrosis.
7 This entity
is characterized by extensive IgG4-positive plasma
cell and T-lymphocyte infiltration of various organs.
It seems that our case could be described as retro-
peritoneal lesions of IgG4-related systemic disease.
Unfortunately, we could not confirm this pos-
sibility because testing of serum IgG4 or staining
of IgG4 in tissue was not available at our hospital.
In conclusion, we have reported an unusual case
of autoimmune thyroiditis with IRPF which showed
good response to steroid treatment. It is important
for the physician to recognize the presence of
autoimmune thyroiditis in the presence of IRPF
and initiate steroid therapy for resolution of both
diseases prior to surgery.
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